GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients

Diabetes Care

Volumn 31, Issue 8, 2008, Pages 1602-1607

  Maruyama, Taro ^a   Oak, Shilpa ^b   Shimada, Akira ^c   Hampe, Christiane S ^b  

^a Saitama Social Insurance Hospital   (Japan)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; EPITOPE; GLIBENCLAMIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILD; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMORAL IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JAPANESE; LATENT AUTOIMMUNE DIABETES IN ADULT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; ANTIBODY PRODUCTION; BLOOD; ENZYMOLOGY; IMMUNOLOGY; JAPAN; MIDDLE AGED; PANCREAS ISLET BETA CELL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; AUTOANTIBODIES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 49649119785     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0235     Document Type: Article

References (20)

1. Turner R, Stratton I, Horton V, et al.: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288-1293, 1997 [erratum in Lancet 351:376, 1998]
2. Fourlanos S, Dotta F, Greenbaum CJ, et al.: Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206-2212, 2005
3. Graham J, Hagopian WA, Kockum I, et al.: Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51:1346-1355, 2002
4. Falorni A, Brozzetti A: Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 19:119-133, 2005
5. Borg H, Gottsater A, Fernlund P, et al.: A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51:1754-1762, 2002
6. Decochez K, Tits J, Coolens JL, Van Gaal L, et al.: High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age: the Belgian Diabetes Registry. Diabetes Care 23:838 -844, 2000
7. Bingley PJ, Bonifacio E, Williams AJK, et al.: Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701-1710, 1997
8. Verge CF, Gianani R, Kawasaki E, et al.: Prediction of type I diabetes in first- degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
9. Padoa CJ, Banga JP, Madec AM, et al.: Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 52: 2689-2695, 2003
10. Gale EA: Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 48:2195-2199, 2005
11. Mire-Sluis A, Gaines Das R, Lernmark A: Standardization of antibody preparations for use in immunogenicity studies: a case study using the World Health Organization International Collaborative Study for Islet Cell Antibodies. Dev Biol (Basel) 112: 153-163, 2003
12. Maruyama T, Oak S, Hall TR, et al.: Auto- antibody epitopes to the smaller isoform of glutamate decarboxylase do not differ in Swedish and Japanese type 1 diabetes patients and may be associated with high- risk human leucocyte antigen class II al- leles. Clin Exp Immunol 150:416-421, 2007
13. Fenalti G, Hampe CS, Arafat Y, et al.: C-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis ofautoreactivity. Diabetes 57:1293-301, 2008
14. Grubin C, Daniels T, Karlsen AE, et al.: The cDNA-directed, in vitro-synthesized nascent peptide of glutamic acid decar- boxylase (GAD2) is the autoantigen in insulin-dependent diabetes (Abstract). Clin Res 40:299A, 1992
15. Kasuga A, Maruyama T, Nakamoto S, et al.: High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun 12:131-135, 1999
16. Falorni A, Calcinaro F: Autoantibodypro- file and epitope mapping in latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:99-106, 2002
17. Hampe CS, Hall TR, Agren A, et al.: Longitudinal changes in epitope recognition of autoantibodies against glutamate decarboxylase 65 (GAD65Ab) inprediabetic adults developing diabetes. Clin Exp Immunol 148:72-78, 2007
18. Desai M, Cull CA, Horton VA, et al.: GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50:2052-2060, 2007
19. Lohmann T, Kellner K, Verlohren HJ, et al.: Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44:1005-1010, 2001
20. Buzzetti R, Di Pietro S, Giaccari A, et al.: High titer of autoantibodies to GAD identifies a specific phenotype of adultonset autoimmune diabetes. Diabetes Care 30:932-938, 2007